|
1
|
Pop MG: Stem cell markers in colon cancer.
Basic Princ Pract Surg. 2019.
|
|
2
|
Coppedè F, Lopomo A, Spisni R and Migliore
L: Genetic and epigenetic biomarkers for diagnosis, prognosis and
treatment of colorectal cancer. World J Gastroenterol. 20:943–956.
2014. View Article : Google Scholar
|
|
3
|
Orjuela S, Menigatti M, Schraml P,
Kambakamba P, Robinson MD and Marra G: The DNA hypermethylation
phenotype of colorectal cancer liver metastases resembles that of
the primary colorectal cancers. BMC Cancer. 20:2902020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Vogel S, Wouters KA, Gottschalk RW, van
Schooten FJ, de Goeij AF, de Bruïne AP, Goldbohm RA, van den Brandt
PA, Weijenberg MP and van Engeland M: Genetic variants of methyl
metabolizing enzymes and epigenetic regulators: Associations with
promoter CpG island hypermethylation in colorectal cancer. Cancer
Epidemiol Biomarkers Prev. 18:3086–3096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta R, Bhatt LK, Johnston TP and
Prabhavalkar KS: Colon cancer stem cells: Potential target for the
treatment of colorectal cancer. Cancer Biol Ther. 20:1068–1082.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spelt L, Sasor A, Ansari D, Hilmersson KS
and Andersson R: The prognostic role of cancer stem cell markers
for long-term outcome after resection of colonic liver metastases.
Anticancer Res. 38:313–320. 2018.PubMed/NCBI
|
|
7
|
Nosrati A, Naghshvar F, Maleki I and
Salehi F: Cancer stem cells CD133 and CD24 in colorectal cancers in
Northern Iran. Gastroenterol Hepatol Bed Bench. 9:132–139.
2016.PubMed/NCBI
|
|
8
|
Kazama S, Kishikawa J, Kiyomatsu T, Kawai
K, Nozawa H, Ishihara S and Watanabe T: Expression of the stem cell
marker CD133 is related to tumor development in colorectal
carcinogenesis. Asian J Surg. 41:274–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schmohl JU and Vallera DA: CD133,
selectively targeting the root of cancer. Toxins (Basel).
8:1652016. View Article : Google Scholar
|
|
10
|
Barzegar Behrooz A, Syahir A and Ahmad S:
CD133: Beyond a cancer stem cell biomarker. J Drug Target.
27:257–269. 2019. View Article : Google Scholar
|
|
11
|
Sahlberg SH, Spiegelberg D, Glimelius B,
Stenerlöw B and Nestor M: Evaluation of cancer stem cell markers
CD133, CD44, CD24: Association with AKT isoforms and radiation
resistance in colon cancer cells. PLoS One. 9:e946212014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto S, Tanaka K, Takeda K, Akiyama H,
Ichikawa Y, Nagashima Y and Endo I: Patients with CD133-negative
colorectal liver metastasis have a poor prognosis after
hepatectomy. Ann Surg Oncol. 21:1853–1861. 2014. View Article : Google Scholar
|
|
13
|
Narita M, Oussoultzoglou E, Chenard MP,
Fuchshuber P, Yamamoto T, Addeo P, Jaeck D and Bachellier P:
Predicting early intrahepatic recurrence after curative resection
of colorectal liver metastases with molecular markers. World J
Surg. 39:1167–1176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen S, Song X, Chen Z, Li X, Li M, Liu H
and Li J: CD133 expression and the prognosis of colorectal cancer:
A systematic review and meta-analysis. PLoS One. 8:e563802013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang K, Xu J, Zhang J and Huang J:
Prognostic role of CD133 expression in colorectal cancer: A
meta-analysis. BMC Cancer. 12:5732012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Geddert H, Braun A, Kayser C, Dimmler A,
Faller G, Agaimy A, Haller F and Moskalev EA: Epigenetic regulation
of CD133 in gastrointestinal stromal tumors. Am J Clin Pathol.
147:515–524. 2017. View Article : Google Scholar
|
|
17
|
Fanali C, Lucchetti D, Farina M, Corbi M,
Cufino V, Cittadini A and Sgambato A: Cancer stem cells in
colorectal cancer from pathogenesis to therapy: Controversies and
perspectives. World J Gastroenterol. 20:923–942. 2014. View Article : Google Scholar
|
|
18
|
Yi JM, Tsai HC, Glöckner SC, Lin S, Ohm
JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, et
al: Abnormal DNA methylation of CD133 in colorectal and
glioblastoma tumors. Cancer Res. 68:8094–8103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dana H, Marmari V, Mahmoodi G,
Mahmoodzadeh H, Ebrahimi M and Mehmandoost N: CD166 as a stem cell
marker? A potential target for therapy colorectal cancer? J Stem
Cell Res Ther. 1:226–229. 2016.
|
|
20
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weichert W, Knösel T, Bellach J, Dietel M
and Kristiansen G: ALCAM/CD166 is overexpressed in colorectal
carcinoma and correlates with shortened patient survival. J Clin
Pathol. 57:1160–1164. 2004. View Article : Google Scholar
|
|
22
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Darvishi B, Boroumandieh S, Majidzadeh-A
K, Salehi M, Jafari F and Farahmand L: The role of activated
leukocyte cell adhesion molecule (ALCAM) in cancer progression,
invasion, metastasis and recurrence: A novel cancer stem cell
marker and tumor-specific prognostic marker. Exp Mol Pathol.
115:1044432020. View Article : Google Scholar
|
|
24
|
Chen C, Zhao S, Karnad A and Freeman JW:
The biology and role of CD44 in cancer progression: Therapeutic
implications. J Hematol Oncol. 11:642018. View Article : Google Scholar
|
|
25
|
Vincent A, Ouelkdite-Oumouchal A, Souidi
M, Leclerc J, Neve B and Van Seuningen I: Colon cancer stemness as
a reversible epigenetic state: Implications for anticancer
therapies. World J Stem Cells. 11:920–936. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tachezy M, Zander H, Gebauer F, Marx A,
Kaifi JT, Izbicki JR and Bockhorn M: Activated leukocyte cell
adhesion molecule (CD166)-its prognostic power for colorectal
cancer patients. J Surg Res. 177:e15–e20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Levin TG, Powell AE, Davies PS, Silk AD,
Dismuke AD, Anderson EC, Swain JR and Wong MH: Characterization of
the intestinal cancer stem cell marker CD166 in the human and mouse
gastrointestinal tract. Gastroenterology. 139:2072–2082.e5. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han S, Yang W, Zong S, Li H, Liu S, Li W,
Shi Q and Hou F: Clinicopathological, prognostic and predictive
value of CD166 expression in colorectal cancer: A meta-analysis.
Oncotarget. 8:64373–64384. 2017. View Article : Google Scholar
|
|
29
|
Beumer J and Clevers H: Regulation and
plasticity of intestinal stem cells during homeostasis and
regeneration. Development. 143:3639–3649. 2016. View Article : Google Scholar
|
|
30
|
Wu XS, Xi HQ and Chen L: Lgr5 is a
potential marker of colorectal carcinoma stem cells that correlates
with patient survival. World J Surg Oncol. 10:2442012. View Article : Google Scholar
|
|
31
|
Zheng Z, Yu H, Huang Q, Wu H, Fu Y, Shi J,
Wang T and Fan X: Heterogeneous expression of Lgr5 as a risk factor
for focal invasion and distant metastasis of colorectal carcinoma.
Oncotarget. 9:30025–30033. 2018. View Article : Google Scholar
|
|
32
|
Hsu HC, Liu YS, Tseng KC, Hsu CL, Liang Y,
Yang TS, Chen JS, Tang RP, Chen SJ and Chen HC: Overexpression of
Lgr5 correlates with resistance to 5-FU-based chemotherapy in
colorectal cancer. Int J Colorectal Dis. 28:1535–1546. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wahab SMR, Islam F, Gopalan V and Lam AK:
The identifications and clinical implications of cancer stem cells
in colorectal cancer. Clin Colorectal Cancer. 16:93–102. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu W, Cao J, Ji Z, Wang J, Jiang T and
Ding H: Co-expression of Lgr5 and CXCR4 characterizes cancer
stem-like cells of colorectal cancer. Oncotarget. 7:81144–81155.
2016. View Article : Google Scholar
|
|
35
|
Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu
Q, Lin J, Tan S, Tian Y, Liao Q and Cao D: Cancer stem cells in
progression of colorectal cancer. Oncotarget. 9:33403–33415. 2017.
View Article : Google Scholar
|
|
36
|
Jang BG, Kim HS, Chang WY, Bae JM, Kim WH
and Kang GH: Expression profile of LGR5 and its prognostic
significance in colorectal cancer progression. Am J Pathol.
188:2236–2250. 2018. View Article : Google Scholar
|
|
37
|
Alizadeh Naini M, Kavousipour S,
Hasanzarini M, Nasrollah A, Monabati A and Mokarram P:
O6-methyguanine-DNA Methyl transferase (MGMT) promoter methylation
in serum DNA of Iranian patients with colorectal cancer. Asian Pac
J Cancer Prev. 19:1223–1227. 2018.PubMed/NCBI
|
|
38
|
Inno A, Fanetti G, Di Bartolomeo M, Gori
S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, de
Braud F, et al: Role of MGMT as biomarker in colorectal cancer.
World J Clin Cases. 2:835–839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cervena K, Siskova A, Buchler T, Vodicka P
and Vymetalkova V: Methylation-based therapies for colorectal
cancer. Cells. 9:15402020. View Article : Google Scholar
|
|
40
|
Kordowski F, Kolarova J, Schafmayer C,
Buch S, Goldmann T, Marwitz S, Kugler C, Scheufele S, Gassling V,
Németh CG, et al: Aberrant DNA methylation of ADAMTS16 in
colorectal and other epithelial cancers. BMC Cancer. 18:7962018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Strnadel J, Woo SM, Choi S, Wang H,
Grendar M and Fujimura K: 3D culture protocol for testing gene
knockdown efficiency and cell line derivation. Bio Protoc.
8:e28742018. View Article : Google Scholar
|
|
42
|
Meršaková S, Holubeková V, Grendár M,
Višňovský J, Ňachajová M, Kalman M, Kúdela E, Žúbor P, Bielik T,
Lasabová Z and Danko J: Methylation of CADM1 and MAL together with
HPV status in cytological cervical specimens serves an important
role in the progression of cervical intraepithelial neoplasia.
Oncol Lett. 16:7166–7174. 2018.
|
|
43
|
R Core Team (2021). R, . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: https://www.R-project.org/
|
|
44
|
World Cancer Research Fund International,
. Colorectal cancer statistics. https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics/April
26–2022
|
|
45
|
Horst D, Kriegl L, Engel J, Kirchner T and
Jung A: Prognostic significance of the cancer stem cell markers
CD133, CD44, and CD166 in colorectal cancer. Cancer Invest.
27:844–850. 2009. View Article : Google Scholar
|
|
46
|
Fang C, Fan C, Wang C, Huang Q, Meng W, Yu
Y, Yang L, Hu J, Li Y, Mo X and Zhou Z: Prognostic value of
CD133+ CD54+ CD44+ circulating
tumor cells in colorectal cancer with liver metastasis. Cancer Med.
6:2850–2857. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Morgan RG, Mortensson E and Williams AC:
Targeting LGR5 in colorectal cancer: Therapeutic gold or too
plastic? Br J Cancer. 118:1410–1418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Miller TJ, McCoy MJ, Hemmings C, Bulsara
MK, Iacopetta B and Platell CF: The prognostic value of cancer
stem-like cell markers SOX2 and CD133 in stage III colon cancer is
modified by expression of the immune-related markers FoxP3, PD-L1
and CD3. Pathology. 49:721–730. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mărgaritescu C, Pirici D, Cherciu I,
Bărbălan A, Cârtână T and Săftoiu A: CD133/CD166/Ki-67 triple
immunofluorescence assessment for putative cancer stem cells in
colon carcinoma. J Gastrointest Liver Dis. 23:161–170. 2014.
View Article : Google Scholar
|
|
50
|
Pietrantonio F, Perrone F, de Braud F,
Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M,
Busico A, et al: Activity of temozolomide in patients with advanced
chemorefractory colorectal cancer and MGMT promoter methylation.
Ann Oncol. 25:404–408. 2014. View Article : Google Scholar
|
|
51
|
Atlasy N, Amidi F, Mortezaee K, Fazeli MS,
Mowla SJ and Malek F: Expression patterns for TETs, LGR5 and BMI1
in cancer stem-like cells isolated from human colon cancer.
Avicenna J Med Biotechnol. 11:156–161. 2019.
|
|
52
|
Wang BB, Li ZJ, Zhang FF, Hou HT, Yu JK
and Li F: Clinical significance of stem cell marker CD133
expression in colorectal cancer. Histol Histopathol. 31:299–306.
2016.
|
|
53
|
Park YY, An CH, Oh ST, Chang ED and Lee J:
Expression of CD133 is associated with poor prognosis in stage II
colorectal carcinoma. Medicine (Baltimore). 98:e167092019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pellacani D, Packer RJ, Frame FM, Oldridge
EE, Berry PA, Labarthe MC, Stower MJ, Simms MS, Collins AT and
Maitland NJ: Regulation of the stem cell marker CD133 is
independent of promoter hypermethylation in human epithelial
differentiation and cancer. Mol Cancer. 10:942011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dame MK, Attili D, McClintock SD, Dedhia
PH, Ouillette P, Hardt O, Chin AM, Xue X, Laliberte J, Katz EL, et
al: Identification, isolation and characterization of human
LGR5-positive colon adenoma cells. Development. 145:dev1530492018.
View Article : Google Scholar
|
|
56
|
Leng Z, Xia Q, Chen J, Li Y, Xu J, Zhao E,
Zheng H, Ai W and Dong J:
Lgr5+CD44+EpCAM+ strictly defines
cancer stem cells in human colorectal cancer. Cell Physiol Biochem.
46:860–872. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Costello JF, Futscher BW, Tano K, Graunke
DM and Pieper RO: Graded methylation in the promoter and body of
the O6-methylguanine DNA methyltransferase (MGMT) gene correlates
with MGMT expression in human glioma cells. J Biol Chem.
269:17228–17237. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Qian X, von Wronski MA and Brent TP:
Localization of methylation sites in the human O6-methylguanine-DNA
methyltransferase promoter: Correlation with gene suppression.
Carcinogenesis. 16:1385–1390. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shen L, Kondo Y, Rosner GL, Xiao L,
Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR,
Einspahr JG, et al: MGMT promoter methylation and field defect in
sporadic colorectal cancer. J Natl Cancer Inst. 97:1330–1338. 2005.
View Article : Google Scholar
|
|
60
|
Fornaro L, Vivaldi C, Caparello C,
Musettini G, Baldini E, Masi G and Falcone A: Pharmacoepigenetics
in gastrointestinal tumors: MGMT methylation and beyond. Front
Biosci (Elite Ed). 8:170–180. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
61
|
Margison GP, Povey AC, Kaina B and
Santibáñez Koref MF: Variability and regulation of
O6-alkylguanine-DNA alkyltransferase. Carcinogenesis. 24:625–635.
2003. View Article : Google Scholar : PubMed/NCBI
|
